Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2, neuropilin-1, syndecan-1 and cellular heparan sulfate
A main clinical parameter of COVID-19 pathophysiology is hypoxia. Here we show that hypoxia decreases the attachment of the receptor-binding domain (RBD) and the S1 subunit (S1) of the spike protein of SARS-CoV-2 to epithelial cells. In Vero E6 cells, hypoxia reduces the protein levels of ACE2 and neuropilin-1 (NRP1), which might in part explain the observed reduction of the infection rate. In addition, hypoxia inhibits the binding of the spike to NCI-H460 human lung epithelial cells by decreasing the cell surface levels of heparan sulfate (HS), a known attachment receptor of SARS-CoV-2. This interaction is also reduced by lactoferrin, a glycoprotein that blocks HS moieties on the cell surface. The expression of syndecan-1, an HS-containing proteoglycan expressed in lung, is inhibited by hypoxia on a HIF-1α-dependent manner. Hypoxia or deletion of syndecan-1 results in reduced binding of the RBD to host cells. Our study indicates that hypoxia acts to prevent SARS-CoV-2 infection, suggesting that the hypoxia signalling pathway might offer therapeutic opportunities for the treatment of COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Emerging Microbes and Infections - 10(2021), 1, Seite 1065-1076 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Endika Prieto-Fernández [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
ACE2 |
|---|
| doi: |
10.1080/22221751.2021.1932607 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ01795049X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ01795049X | ||
| 003 | DE-627 | ||
| 005 | 20230310093736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/22221751.2021.1932607 |2 doi | |
| 035 | |a (DE-627)DOAJ01795049X | ||
| 035 | |a (DE-599)DOAJaf10c8771b7745ab83dcafd99d208588 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC109-216 | |
| 050 | 0 | |a QR1-502 | |
| 100 | 0 | |a Endika Prieto-Fernández |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hypoxia reduces cell attachment of SARS-CoV-2 spike protein by modulating the expression of ACE2, neuropilin-1, syndecan-1 and cellular heparan sulfate |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a A main clinical parameter of COVID-19 pathophysiology is hypoxia. Here we show that hypoxia decreases the attachment of the receptor-binding domain (RBD) and the S1 subunit (S1) of the spike protein of SARS-CoV-2 to epithelial cells. In Vero E6 cells, hypoxia reduces the protein levels of ACE2 and neuropilin-1 (NRP1), which might in part explain the observed reduction of the infection rate. In addition, hypoxia inhibits the binding of the spike to NCI-H460 human lung epithelial cells by decreasing the cell surface levels of heparan sulfate (HS), a known attachment receptor of SARS-CoV-2. This interaction is also reduced by lactoferrin, a glycoprotein that blocks HS moieties on the cell surface. The expression of syndecan-1, an HS-containing proteoglycan expressed in lung, is inhibited by hypoxia on a HIF-1α-dependent manner. Hypoxia or deletion of syndecan-1 results in reduced binding of the RBD to host cells. Our study indicates that hypoxia acts to prevent SARS-CoV-2 infection, suggesting that the hypoxia signalling pathway might offer therapeutic opportunities for the treatment of COVID-19. | ||
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a hypoxia | |
| 650 | 4 | |a ACE2 | |
| 650 | 4 | |a heparan sulfate | |
| 650 | 4 | |a syndecan-1 | |
| 653 | 0 | |a Infectious and parasitic diseases | |
| 653 | 0 | |a Microbiology | |
| 700 | 0 | |a Leire Egia-Mendikute |e verfasserin |4 aut | |
| 700 | 0 | |a Laura Vila-Vecilla |e verfasserin |4 aut | |
| 700 | 0 | |a Alexandre Bosch |e verfasserin |4 aut | |
| 700 | 0 | |a Adrián Barreira-Manrique |e verfasserin |4 aut | |
| 700 | 0 | |a So Young Lee |e verfasserin |4 aut | |
| 700 | 0 | |a Ana García-del Río |e verfasserin |4 aut | |
| 700 | 0 | |a Asier Antoñana-Vildosola |e verfasserin |4 aut | |
| 700 | 0 | |a Borja Jiménez-Lasheras |e verfasserin |4 aut | |
| 700 | 0 | |a Leire Moreno-Cugnon |e verfasserin |4 aut | |
| 700 | 0 | |a Jesús Jiménez-Barbero |e verfasserin |4 aut | |
| 700 | 0 | |a Edurne Berra |e verfasserin |4 aut | |
| 700 | 0 | |a June Ereño-Orbea |e verfasserin |4 aut | |
| 700 | 0 | |a Asis Palazon |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Emerging Microbes and Infections |d Taylor & Francis Group, 2013 |g 10(2021), 1, Seite 1065-1076 |w (DE-627)DOAJ00011538X |x 22221751 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2021 |g number:1 |g pages:1065-1076 |
| 856 | 4 | 0 | |u https://doi.org/10.1080/22221751.2021.1932607 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/af10c8771b7745ab83dcafd99d208588 |z kostenfrei |
| 856 | 4 | 0 | |u https://www.tandfonline.com/doi/10.1080/22221751.2021.1932607 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2222-1751 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2021 |e 1 |h 1065-1076 | ||